The purpose of this announcement is to enter into agreements with pharmaceutical companies

Company within the meaning of § 130a sec. 8 sentence 1 SGB V. The invitation to participate may only be sent to:

pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of

of § 4 Abs. 18 Arzneimittelgesetz. It is not an open procedure according to § 15 VgV

in conjunction with § 119 Abs. 3 GWB, but a publication of the invitation to conclude/join of/

discount agreements with non-negotiable conditions fixed for all participants, including

the amount of the discount. Contractual partners may have an unlimited number of pharmaceutical companies or

Employee associations of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz.

This announcement serves to conclude agreements on the active ingredient "4-hydroxybutanoic acid (ATC code: N07XX04)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements). 130a, Paragraph 8, Clause 1 of Book V of the Social Code, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) to conclude / join discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the systematics of this form. There is no limit to the number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the Medicinal Products Act esetz (AMG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "brinzolamide, brimonidine (ATC CODE: S01EC54)" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Brivudine (ATC CODE: J05AB15) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "cefpodoxime (ATC CODE: J01DD13) pharmaceutical form: GSE, PSE, SAF, TSA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "chlorprothixene (ATC CODE: N05AF03) dosage form: FTA, UTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "clomipramine (ATC CODE: N06AA04) dosage form: FTA, TAB, UTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Colestyramine (ATC CODE: C10AC01) pharmaceutical form: GSE, PSE, PUL" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "Desmopressin (ATC-CODE: H01BA02) pharmaceutical form: LOE, NAS" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "diazepam (ATC-CODE: N05BA01) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "efavirenz (ATC-CODE: J05AG03) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The present announcement serves to conclude agreements on the active ingredient "iron carboxymaltose (ATC code: B03AC)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book Five (SGB V) (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form. Contractual partners can include an unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies in the sense of of § 4 Paragraph 18 of the Medicinal Products Act etz (AMG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "Abacavir (ATC CODE: J05AF06) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "fluorouracil, salicylic acid (ATC CODE: L01BC52)" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "fluticasone, salmeterol (ATC CODE: R03AK06) dosage form: DOS, IHP" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "glycerol trinitrate (ATC CODE: C01DA02) pharmaceutical form: LOE, SPR" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "ibandronic acid (ATC CODE: M05BA06) dosage form: FER" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

This announcement serves to conclude agreements on the active ingredient "Leuprorelin acetate (ATC code: L02AE02)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements) Paragraph 8 sentence 1 SGB V, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 Paragraph 18 of the German Medicines Act (AMG) Conclusion / joining of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the systematics of this form Within the meaning of Section 4, Paragraph 18 of the Drug Ordinance set (AMG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Levocetirizine - apothekenpflichtig (ATC-CODE: R06AE09) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "Solutions for parenteral nutrition combinations ATC-Code B05BA10 (ATC-CODE: B05BA10)" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "lovastatin (ATC-CODE: C10AA02) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The present announcement serves to conclude agreements on the active ingredient "Macrogol (only pharmaceuticals) (ATC code: A06AD65)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements). According to Section 130a, Paragraph 8, Clause 1 of Book V of the Social Code, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 Paragraph 18 of the German Medicines Act (AMG) the request to conclude / join discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the systematics of this form. Contractual partners can have an unlimited number of pharmaceutical entrepreneurs or employee associations pharmaceutical entrepreneur within the meaning of Section 4 Paragraph 18 Medic imittelgesetz (AMG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "memantine (ATC code: N06DX01) dosage form: LSE" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "acemetacin (ATC CODE: M01AB11) dosage form: HKP" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The present announcement serves to conclude agreements on the active ingredient "Midazolam (ATC code: N05CD08)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form. Contractual partners can include an unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies in the sense of of Section 4, Paragraph 18 of the Medicines Act (AMG ) become. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Minocycline (ATC code: J01AA08) dosage form: FTA, HKP, KAP" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "moxifloxacin (ATC code: J01MA14) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "naltrexone (ATC code: N07BB04) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "nevirapine (ATC code: J05AG01) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "nitrofurantoin (ATC code: J01XE01) pharmaceutical form: KAP, TAB, UTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "norfloxacin (ATC code: J01MA06) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "ofloxacin (ATC code: J01MA01) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

This announcement serves to conclude agreements on the active ingredient "Oseltamivir (ATC code: J05AH02)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount agreements with non-negotiable conditions for all participants including the amount of the discount. The corresponding information under IV.1.1) is only due to the systematics of this form of Section 4, Paragraph 18 of the Medicines Act (A MG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

This announcement serves to conclude agreements on the active ingredient "Peginterferon beta-1-a (ATC code: L03AB13)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book Five (SGB V) (discount agreements) . According to Section 130a, Paragraph 8, Clause 1 of Book V of the Social Code, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) Publication of the invitation to conclude / join discount contracts with non-negotiable conditions specified for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the system of this form. Contractual partners can have an unlimited number of pharmaceutical companies or Workers' associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18, Pharmaceuticals elgesetz (AMG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The present announcement serves to conclude agreements on the active ingredient "Albendazole (ATC code: P02CA03)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, Book V (Book V) (discount agreements) 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) / Accession of / to discount agreements with non-negotiable conditions for all participants including the amount of the discount. The corresponding information under IV.1.1) is only due to the systematics of this form of Section 4, Paragraph 18 of the German Medicines Act (AM G) will be. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "Pentoxifylline (ATC code: C04AD03) dosage form: RED, REK, RET, prolonged-release film tablets" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Piretanide (ATC code: C03CA03) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "pyridostigmine bromide (ATC code: N07AA02) dosage form: TAB, UTA" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Quinapril, HCT (ATC code: C09BA06) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "ramipril, piretanide (ATC code: C09BA05) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "tamoxifen (ATC code: L02BA01) dosage form: FTA, TAB" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Book V (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The present announcement serves to conclude agreements on the active ingredient "Triamcinolone Depot (ATC Code: H02AB08)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements). 130a, Paragraph 8, Clause 1 of Book V of the Social Code, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 Paragraph 18 of the German Medicines Act (AMG). This is not an open procedure, but a publication of the invitation to conclude / join discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the systematics of this form. There is no limit to the number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 Paragraph 18 Medicinal Products set (AMG). The information under II.2.5) is owed to the systematics of this publication form. The conclusion of a contract or a joining takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "Voriconazole (ATC code: J02AC03) dosage form: PIF, PSE" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Zuclopenthixol (ATC code: N05AF05) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Zuclopenthixol (ATC code: N05AF05) dosage form: ILO" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active substance "amiloride, hydrochlorothiazide (ATC CODE: C03EA01) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Book V (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "amlodipine, bisoprolol (ATC CODE: C07FB07) dosage form: TAB" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Amlodipine, Candesartan (ATC-CODE: C09DB07) dosage form: FTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "amlodipine, hydrochlorothiazide, ramipril (ATC CODE: C09BX03)" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Bezafibrate (ATC CODE: C10AB02) dosage form: FTA, UTA" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) sent by e-mail to openhouse.rabattvertrag2023-03@kbs.de to KBS.

The earliest start date of the contract is 01.05.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.04.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.